Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients

Clinical Microbiology Reviews

Volumn 27, Issue 4, 2014, Pages 753-782

  Dalhoff, Axel ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; AZTREONAM; BACTERIAL DNA; CIPROFLOXACIN; COLISTIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ACHROMOBACTER XYLOSOXIDANS; AEROSOL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL VIRULENCE; BURKHOLDERIA CEPACIA; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION CONTROL; LUNG FUNCTION; MICROBIOME; NONHUMAN; PATHOGENESIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; BACTERIAL INFECTIONS; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; LUNG; MICROBIOLOGY; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTIONS; SPUTUM;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; LUNG; PSEUDOMONAS INFECTIONS; SPUTUM;

EID: 84907734820     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00022-14     Document Type: Article

References (374)

1. Littlewood KJ, Higashi K, Capkun-Niggli G, Balp MM, Doering G, Tiddens HA, Angyalosi G. 2012. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibro-sis. J. Cyst. Fibros. 11:419-426. http://dx.doi.org/10.1016/j.jcf.2012.03.010.
2. Le J, Ashley ED, Neuhauser MM, Brown J, Gentry C, Klepser ME, Marr AM, Schiller D, Schwiesow JN, Tice S, vandenBussche HL, Wood GC. 2010. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 30:562-584. http://dx.doi.org/10.1592/phco.30.6.562.
3. Heijerman H, Westerman E, Conway S, Touw D. 2009. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros. 8:295-315. http://dx.doi.org/10.1016/j.jcf.2009.04.005.
4. Geller DE. 2009. Aerosol antibiotics in cystic fibrosis. Respir. Care 54: 658-670.
5. Wood GC. 2011. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert. Rev. Anti Infect. Ther. 9:993-1000. http://dx.doi.org/10.1586/eri.11.126.
6. Høiby N. 2011. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 9:32. http://dx.doi.org/10.1186/1741-7015-9-32.
7. Høiby N, Ciofu O, Bjarnsholt T. 2010. Pseudomonas aeruginosa bio-films in cystic fibrosis. Future Microbiol. 5:1663-1674. http://dx.doi.org/10.2217/fmb.10.125.
8. Hauser AR, Jain M, Bar-Meir M, McColley SA. 2011. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Mi-crobiol. Rev. 24:29-70. http://dx.doi.org/10.1128/CMR.00036-10.
9. Starner TD, Zhang N, Kim G, Apicella MA, McCray PB Jr. 2006. Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am. J. Respir. Crit. Care Med. 174:213-220.
10. Desai M, Buhler T, Weller PH, Brown MR. 1998. Increasing resistance of planktonic and biofilm cultures of Burkholderia cepacia to ciprofloxa-cin and ceftazidime during exponential growth. J. Antimicrob. Che-mother. 42:153-160. http://dx.doi.org/10.1093/jac/42.2.153.
11. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, MacLeod C, Aaron SD, Harbour C. 2005. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibro-sis under aerobic, anaerobic, and biofilm conditions. J. Clin. Microbiol. 43:5085-5090. http://dx.doi.org/10.1128/JCM.43.10.5085-5090.2005.
12. Savoia D, Zucca M. 2007. Clinical and environmental Burkholderia strains: biofilm production and intracellular survival. Curr. Microbiol. 54:440-444. http://dx.doi.org/10.1007/s00284-006-0601-9.
13. Cunha MV, Sousa SA, Leitao JH, Moreira LM, Videira PA, Sa-Correia I. 2004. Studies on the involvement of the exopolysaccharide produced by cystic fibrosis-associated isolates of Burkholderia cepacia complex in bio-film formation and in persistence of respiratory infections. J. Clin. Mi-crobiol. 42:3052-3058. http://dx.doi.org/10.1128/JCM.42.7.3052-3058.2004.
14. Pietruczuk-Padzik A, Stefanska J, Semczuk K, Dzierzanowska D, Tyski S. 2010. Evaluation of biofilm formation by Staphylococcus aureus isolated from sputum of cystic fibrosis patients. Med. Dosw. Mikrobiol. 62:1-8.
15. Blazquez J. 2003. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin. Infect. Dis. 37:1201-1209. http://dx.doi.org/10.1086/378810.
16. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254. http://dx.doi.org/10.1126/science.288.5469.1251.
17. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL, Oliver A. 2005. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 49:3382-3386. http://dx.doi.org/10.1128/AAC.49.8.3382-3386.2005.
18. Besier S, Zander J, Kahl BC, Kraiczy P, Brade V, Wichelhaus TA. 2008. The thymidine-dependent small colony variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 52:2183-2189. http://dx.doi.org/10.1128/AAC.01395-07.
19. Watson ME Jr, Burns J., Smith AL. 2004. Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150:2947-2958. http://dx.doi.org/10.1099/mic.0.27230-0.
20. Oliver A, Levin BR, Juan C, Baquero F, Blazquez J. 2004. Hypermu-tation and the preexistence of antibiotic-resistant Pseudomonas aerugi-nosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233. http://dx.doi.org/10.1128/AAC.48.11.4226-4233.2004.
21. Oliver A, Mena A. 2010. Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance. Clin. Microbiol. Infect. 16:798-808. http://dx.doi.org/10.1111/j.1469-0691.2010.03250.x.
22. Oliver A. 2010. Mutators in cystic fibrosis chronic lung infection: prevalence, mechanism, and consequences for antimicrobial therapy. Int. J. Med. Microbiol. 300:563-572. http://dx.doi.org/10.1016/j.ijmm.2010.08.009.
23. Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF, Leclerq R. 2003. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hy-permutable strains. J. Infect. Dis. 187:1709-1716. http://dx.doi.org/10.1086/374937.
24. Bianconi I, Milani A, Cigana C, Paroni M, Levesque RC, Bertoni G, Bragonzi A. 2011. Positive signature-tagged mutagenesis in Pseudomo-nas aeruginosa: tracking patho-adaptive mutations promoting airways chronic infection. PLoS Pathog. 7:1270. http://dx.doi.org/10.1371/journal.ppat.1001270.
25. Sanders LH, Devadoss B, Raja GV, O’Connor J, Su S, Wozniak DJ, Hassett DJ, Berdis AJ, Sutton MD. 2011. Epistatic roles of Pseudomonas aeruginosa MutS and DinB (DNA Pol IV) in coping with reactive oxygen species-induced DNA damage. PLoS One 6:e18824. http://dx.doi.org/10.1371/journal.pone.0018824.
26. Hogardt M, Hoboth C, Schmoldt S, Henke C, Bader L, Heesemann J. 2007. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates from chronic pulmonary infection in patients with cystic fibrosis. J. Infect. Dis. 195:70-80. http://dx.doi.org/10.1086/509821.
27. Canfield GS, Schwingel JM, Foley MH, Vore KL, Boonanantana-sarn K, Gill AL, Sutton MD, Gill SR. 2013. Evolution in fast forward: a potential role for mutators in accelerating Staphylococcus aureus pathoadaptation. J. Bacteriol. 195:615-628. http://dx.doi.org/10.1128/JB.00733-12.
28. Levy J. 1986. Antibiotic activity in sputum. J. Pediatr. 108:841. http://dx.doi.org/10.1016/S0022-3476(86)80755-7.
29. Ramphal R, Lhermitte M, Filliat M, Roussel P. 1988. The binding of anti-pseudomonal antibiotics to macro-molecules from cystic fibrosis sputum. J. Antimicrob. Chemother. 22:483. http://dx.doi.org/10.1093/jac/22.4.483.
30. Haussler S, Ziegler I, Lottel A, von Gotz F, Rohde M, Wehmhohner D, Saravanamuthu S, Tümmler B, Steinmetz I. 2003. Highly adherent small-colony variants of Pseudomonas aeruginosa in cystic fibrosis lung infection. J. Med. Microbiol. 52:295-301. http://dx.doi.org/10.1099/jmm.0.05069-0.
31. Foweraker JE, Laughton CR, Brown DF, Bilton D. 2005. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother. 55:921-927. http://dx.doi.org/10.1093/jac/dki146.
32. Govan JR, Nelson JW. 1992. Microbiology of lung infection in cystic fibrosis. Br. Med. Bull. 48:912-930.
33. Kahl B, Herrmann M, Everding AS, Koch HG, Becker K, Harms E, Proctor RA, Peters G. 1998. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J. Infect. Dis. 177:1023-1029. http://dx.doi.org/10.1086/515238.
34. Haussler S, Lehmann C, Breselge C, Rohde M, Classen M, Tümmler B. 2003. Fatal outcome of lung transplantation in cystic fibrosis patients due to small-colony variants of the Burkholderia cepacia complex. Eur. J. Clin. Microbiol. Infect. Dis. 22:249-253.
35. Proctor RA, von Eiff C, Kahl B, Becker K, McNamara P, Herrmann M, Peters G. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 4:295-305. http://dx.doi.org/10.1038/nrmicro1384.
36. Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Denis O, Tulkens P, van Bambeke F. 2013. Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data. J. Antimicrob. Chemother. 68:1455-1464. http://dx.doi.org/10.1093/jac/dkt072.
37. Chmiel JF, Konstan M., Elborn JS. 2013. Antibiotic and antiinflammatory therapies for cystic fibrosis. Cold Spring Harb. Perpect. Med. 3:9779. http://dx.doi.org/10.1101/cshperspect.a009779.
38. Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V. 2009. Recurrent exacerbations affect FEV1 decline in adult patients with cystic fibrosis. Respir. Med. 103:407-413. http://dx.doi.org/10.1016/j.rmed.2008.09.024.
39. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. 1990. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am. Rev. Respir. Dis. 141:914.
40. Dalhoff A. 2012. Resistance surveillance studies: a multifacetted problem—the fluoroquinolone example. Infection 40:239-262. http://dx.doi.org/10.1007/s15010-012-0257-2.
41. Dalhoff A. 2012. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip. Perspect. Infect. Dis. 2012: 976273. http://dx.doi.org/10.1155/2012/976273.
42. Llanes C, Pourcel C, Richardot C, Plesiat P, Fichant G, Cavallo JD, Merens A. 2013. Diversity of [3-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicenre study. J. Antimicrob. Chemother. 68:1763-1771. http://dx.doi.org/10.1093/jac/dkt115.
43. Pitt TL, Sparrow M, Warner M, Stefanidou M. 2003. Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 58:794-796. http://dx.doi.org/10.1136/thorax.58.9.794.
44. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL. 2010. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr. Pulmonol. 45:363-370. http://dx.doi.org/10.1002/ppul.21198.
45. Valenza G, Tappe D, Turnwald D, Frosch M, König C, Heberstreit H, Abele-Horn M. 2008. Prevalence and antimicrobial susceptibilities of microorganisms isolated from sputa of patients with cystic fibrosis. J. Cyst. Fibros. 7:123-127. http://dx.doi.org/10.1016/j.jcf.2007.06.006.
46. Parkins MD, Sibley CD, Elborn JS. 2011. Multi-drug resistant Pseu-domonas aeruginosa in cystic fibrosis. Part 1: epidemiology, mechanisms and clinical implications. Curr. Med. Lit. Cyst. Fibros. 1:69-73.
47. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34: 634-640. http://dx.doi.org/10.1086/338782.
48. Dalhoff A, Schmitz FJ. 2003. Antibacterial activity and pharmacody-namics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22:203-221.
49. Craig WA, Andes DR. 2003. Pharmacodynamics of quinolone antimicrobial agents, p 147-155. In Hooper DC, Rubinstein E (ed), Quinolone antimicrobial agents, 3rd ed. ASM Press, Washington, DC.
50. Craig WA, Ebert SC. 1990. Killing and regrowth of bacteria in vitro: a review. Scand. J. Infect. Dis. 74:63-70.
51. Martinez MN, Papich MG, Drusano GL. 2012. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob. Agents Che-mother. 56:2795-2805. http://dx.doi.org/10.1128/AAC.05360-11.
52. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tummey MM, Wolfgang MC. 2012 The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 7:e45001. http://dx.doi.org/10.1371/journal.pone.0045001.
53. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U, Andersen GL, Brown R, Fujimura KE, Wu B, Tran D, Koff J, Kleinhenz ME, Nielson D, Brodie EL, Lynch SV. 2010. Airway micro-biota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 5:e11044. http://dx.doi.org/10.1371/journal.pone.0011044.
54. Stressmann FA, Rogers GB, van der Gast C, Marsh P, Vermeer LC, Carroll MP, Hoffman L, Daniels TWV, Patel N, Bruce KD. 2012. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting adult cystic fibrosis lung show stability and resilience. Thorax 67:867-873. http://dx.doi.org/10.1136/thoraxjnl-2011-200932.
55. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, Cavalcoli JD, vanDevanter DR, Murraay S, Li J., Young VB, LiPuma JJ. 2012. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc. Natl. Acad. Sci. U. S. A. 109:5809-5814. http://dx.doi.org/10.1073/pnas.1120577109.
56. Pier GB. 2012. The challenges and promises of new therapies for cystic fibrosis. J. Exp. Med. 209:1235-1239. http://dx.doi.org/10.1084/jem.20121248.
57. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B. 2013. Cystic fibrosis pulmonary guidelines. Am. J. Respir. Crit. Care Med. 187:680-689. http://dx.doi.org/10.1164/rccm.201207-1160OE.
58. LiPuma JJ. 2010. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23:299-323. http://dx.doi.org/10.1128/CMR.00068-09.
59. Hogardt M, Schmoldt S, Götzfried M, Adler K, Heesemann J. 2004. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J. Antimicrob. Che-mother. 54:1057-1061. http://dx.doi.org/10.1093/jac/dkh470.
60. Schülin T. 2002. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J. Anti-microb. Chemother. 49:403-406. http://dx.doi.org/10.1093/jac/49.2.403.
61. Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S. 2001. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J. Clin. Microbiol. 39:3942-3945. http://dx.doi.org/10.1128/JCM.39.11.3942-3945.2001.
62. Jacquier H, le Monnier A, Carbonnelle E, Corvec S, Illiaquer M, Bille E, Zahar JR, Jaureguy F, Fihman V, Tankovic J, Cattoir V, Gmc Study Group. 2012. In vitro antimicrobial activity of “last-resort” antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates. Microb. Drug Resist. 18:396-401. http://dx.doi.org/10.1089/mdr.2011.0195.
63. Saiman L, Chen Y, San Gabriel P, Knirsch C. 2002. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46:1105-1107. http://dx.doi.org/10.1128/AAC.46.4.1105-1107.2002.
64. Zhou J, Chen Y, Tabibi S, Alba L, Garber E, Saiman L. 2007. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob. Agents Che-mother. 51:1085-1088. http://dx.doi.org/10.1128/AAC.00954-06.
65. Traczewski MM, Brown SD. 2006. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from cystic fibrosis and non-cystic fibrosis patients. Antimicrob. Agents Chemother. 50:819-821. http://dx.doi.org/10.1128/AAC.50.2.819-821.2006.
66. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E. 1999. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 43:213-217.
67. King P, Lomosvskaya O, Griffith DC, Burns J., Dudley MN. 2010. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob. Agents Chemother. 54:143-148. http://dx.doi.org/10.1128/AAC.00248-09.
68. Bauernfeind A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clina-floxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40: 639-651. http://dx.doi.org/10.1093/jac/40.5.639.
69. Morosini MI, Garcia-Castillo M, Loza E, Perez-Vazquez M, Baquero F, Canton R. 2005. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J. Clin. Microbiol. 43:4480-4485. http://dx.doi.org/10.1128/JCM.43.9.4480-4485.2005.
70. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubvert M, Rolain JM. 2012. Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti Infect. Ther. 10:917-934. http://dx.doi.org/10.1586/eri.12.78.
71. Oermann CM, McCoy K., Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. 2011. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J. Antimicrob. Chemother. 66:2398-2404. http://dx.doi.org/10.1093/jac/dkr303.
72. Canton R, Valdezate S, Vindel A, DelSaz BS, Maiz L, Baquero F. 2003. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fi-brosis isolates. Pediatr. Pulmonol. 35:99-107. http://dx.doi.org/10.1002/ppul.10216.
73. Govan JRW. 2006. Multiresistant pulmonary infection in cystic fibro-sis—what does resistant mean? J. Med. Microbiol. 55:1615-1617. http://dx.doi.org/10.1099/jmm.0.46884-0.
74. Moskowitz S, Foster J, Emerson J, Burns J. 2004. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42:1915-1922. http://dx.doi.org/10.1128/JCM.42.5.1915-1922.2004.
75. Mesa Espanola de Normalizacionde la Sensibilidad y Resistania a los Antimicrobianos. 2005. Recomendaciones del grupo MENSURA para la seleccion de antimicroanosenel estudio de lasensibilidadycriterios para la interpretacion del antibiograma. MENSURA, Madrid, Spain.
76. Macdonald D, Cuthbertson L, Doherty C, Campana S, Ravenni N, Taccetti G, Govan JRW. 2010. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified? J. Antimicrob. Chemother. 65:2373-2375. http://dx.doi.org/10.1093/jac/dkq342.
77. Høiby N, Frederiksen B, Pressler. 2005. Eradication of early Pseudomo-nas aeruginosa infection. J. Cyst. Fibros. 4:49-54. http://dx.doi.org/10.1016/j.jcf.2005.05.018.
78. van Devanter DR, van Dalfsen JM, Burns J., Mayer-Hamblett N. 10 September 2013. In vitro antibiotic susceptibility of initial Pseudomonas aeruginosa isolates from United States cystic fibrosis patients. J. Pediatr. Infect. Dis. http://dx.doi.org/10.1093/jpids/pit052.
79. Gilligan PH. 2006. Is there value in susceptibility testing of Pseudomonas aeruginosa causing chronic infection in patients with cystic fibrosis? Expert Rev. Anti Infect. Ther. 4:711-715. http://dx.doi.org/10.1586/14787210.4.5.711.
80. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomized, double-blind, controlled clinical trial. Lancet 366:463-471. http://dx.doi.org/10.1016/S0140-6736(05)67060-2.
81. Clinical and Laboratory Standards Institute. 2006. Methods for antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—7th ed. CLSI document M7-A7. CLSI, Wayne, PA.
82. Workentine ML, Sibley CD, Glezerson B, Purighalla S, Norgaard-Gron JC, Parkins MD, Rabin HR, Surette MG. 2013 Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS One 8:e60225. http://dx.doi.org/10.1371/journal.pone.0060225.
83. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D’Argenio DA, Miller SI, Ramsey BW, Speert DP, Maskovitz SM, Burns J., Kaul R, Olson MV. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 103:8487-8849. http://dx.doi.org/10.1073/pnas.0602138103.
84. Damkier S, Yang L, Molin S, Jelsbak L. 22 April 2013. Evolutionary remodeling of global regulatory networks during long-term bacterial adaptation to human hosts. Proc. Natl. Acad. Sci. U. S. A. http://dx.doi.org/10.1073/pnas.1221466110.
85. Sing CF, Risser DR, Howatt WF, Erickson RP. 1982. Phenotypic heterogeneityin cystic fibrosis. Am. J.Med. Genet. 13:179-195. http://dx.doi.org/10.1002/ajmg.1320130209.
86. Harrison F. 2007. Microbial ecology of the cystic fibrosis lung. Microbiology 153:917-923. http://dx.doi.org/10.1099/mic.0.2006/004077-0.
87. Fothergill JL, Mowat E, Ledson MJ, Walshaw MJ, Winstanley C. 2010. Fluctuations in phenotypes and genotypes within populations of Pseu-domonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J. Med. Microbiol. 59:472-481, 2010. http://dx.doi.org/10.1099/jmm.0.015875-0.
88. Tramper-Stranders GA, van der Ent CK, Wolfs TFW, Kimpen JLL, Fleer A, Johansen U, Johansen HK, Hoiby N. 2008. Pseudomonas aeruginosa diversity in distinct paediatric patient groups. Clin. Micro-biol. Infect. 14:935-941. http://dx.doi.org/10.1111/j.1469-0691.2008.02054.x.
89. Pournaras S, Ikonomidis A, Markogiannakis A, Maniatis AN, Tsakris A. 2005. Heteroresistance to carbapenems in Acinetobacter baumannii. J. Antimicrob. Chemother. 55:1055-1056. http://dx.doi.org/10.1093/jac/dki115.
90. Pournaras S, Ikonomidis A, Markogiannakis A, Spanakis N, Maniatis AN, Tsakris A. 2007. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems. J. Med. Microbiol. 56:66-70. http://dx.doi.org/10.1099/jmm.0.46816-0.
91. Ikonomidis A, Tsakris A, Kantzanou M, Spanakis N, Maniatis AN, Pournaras S. 2008. Efflux system overexpression and decreased OprD contribute to the carbapenem heterogeneity in Pseudomonas aeruginosa. FEMS Microbiol. Lett. 279:36-39. http://dx.doi.org/10.1111/j.1574-6968.2007.00997.x.
92. Hermes DM, Pormann Pitt C, Lutz L, Teixeira AB, Ribeiro VB, Netto B, Martins AF, Zavacki AP, Barth AL. 2013. Evaluation of heteroresis-tance to polymyxin B among carbapenem-susceptible and-resistant Pseudomonas aeruginosa. J.Med. Microbiol. 62:1184-1189. http://dx.doi.org/10.1099/jmm.0.059220-0.
93. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50:2946-2950. http://dx.doi.org/10.1128/AAC.00103-06.
94. Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge J., Yu HH, Nation RL, Li J. 2009. Colistin hetero-resistance in multidrug-resistant Acineto-bacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J. Infect. 58:138-144. http://dx.doi.org/10.1016/j.jinf.2008.11.002.
95. Hawley JS, Murray CK, Jorgensen JH. 2008. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Anti-microb. Agents Chemother. 52:351-352. http://dx.doi.org/10.1128/AAC.00766-07.
96. Hung KH, Wang MC, Huang AH, Yan JJ, Wu JJ. 2012. Heteroresis-tance to cephalosporins and penicillins in Acinetobacter baumannii. J. Clin. Microbiol. 50:721-726. http://dx.doi.org/10.1128/JCM.05085-11.
97. Dalhoff A. 1991. Clinical perspectives of quinolone resistance in Pseu-domonas aeruginosa, p 221-239. In Homma JY, Tanimoto H, Holder IA, Hoiby N, D¨ oring G (ed), Pseudomonas aeruginosa in human disease. Antibiotics and chemotherapy, vol 44. Karger, Basel, Switzerland.
98. Irvin RT, Govan JWR, Fyfe JAM, Costerton JW. 1981. Heterogeneity of antibiotic resistance in mucoid isolates of Pseudomonas aeruginosa obtained from cystic fibrosis patients: role of outer membrane proteins. Antimicrob. Agents Chemother. 19:1056-1063. http://dx.doi.org/10.1128/AAC.19.6.1056.
99. Govan JRW, Doherty C, Glass S. 1987. Rational parameters for antibiotic therapy in patients with cystic fibrosis. Infection 15:300-307. http://dx.doi.org/10.1007/BF01644142.
100. Silbert S, Barth AL, Sader HS. 2001. Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patients. J. Clin. Microbiol. 39: 3976-3981. http://dx.doi.org/10.1128/JCM.39.11.3976-3981.2001.
101. Gillham MI, Sundaram S, Laughton CR, Haworth CS, Bilton D, Foweraker JE. 2009. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. J. Anti-microb. Chemother. 63:728-732. http://dx.doi.org/10.1093/jac/dkp007.
102. Goerke C, Wolz C. 2010. Adaptation of Staphylococcus aureus to the cystic fibrosis lung. Int. J. Med. Microbiol. 300:520-555. http://dx.doi.org/10.1016/j.ijmm.2010.08.003.
103. Goerke C, Köller J, Wolz C. 2006. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus au-reus. Antimicrob. Agents Chemother. 50:171-177. http://dx.doi.org/10.1128/AAC.50.1.171-177.2006.
104. Goerke C, Matias Papenberg S, Dasbach S, Dietz K, Ziebach R, Kahl BC, Wolz C. 2004. Increased frequency of genomic alterations in Staph-ylococcus aureus during chronic infection is in part due to phage mobilization. J. Infect. Dis. 189:724-734. http://dx.doi.org/10.1086/381502.
105. Goerke C, Wirtz C, Flückinger U, Wolz C. 2006. Extensive phage dynamics in Staphylococcus aureus contribute to adaptation to the human host during infection. Mol. Microbiol. 61:1673-1685. http://dx.doi.org/10.1111/j.1365-2958.2006.05354.x.
106. McAdam PR, Holmes A, Templeton KE, Fitzgerald JR. 2011. Adaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient. PLoS One 6:e24301. http://dx.doi.org/10.1371/journal.pone.0024301.
107. Glikman D, Siegel JD, David MZ, Okoro NM, Boyle-Vavra S, Dowell ML, Daum RS. 2008. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S. au-reus. Chest 133:1381-1387. http://dx.doi.org/10.1378/chest.07-2437.
108. Lima DF, Brazao NB, Folescu TW, Neves FP, Ferreira AG, Santos EA, Marques EA, Leao RS. 2014. Panton-Valentine leukocidin (PVL) gene carriage among Staphylococcus aureus strains with SCCmec types I, III, IV, and V recovered from cystic fibrosis patients in Brazil. Diagn. Micro-biol. Infect. Dis. 78:59-62. http://dx.doi.org/10.1016/j.diagmicrobio.2013.10.004.
109. Champion EA, Miller MB, Popowitch EB, Hobbs MM, Saiman L, Mulebach MS, STAR-CF Study Team. 2014. Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis. Pediatr. Pulmonol. 49:230-237. http://dx.doi.org/10.1002/ppul.22815.
110. Stranden AM, Roos M, Berger-Bächi B. 1996. Glutamine synthase and heteroresistance in methicillin-resistant Staphylococcus aureus. Microb. Drug Resist. 2:201-207. http://dx.doi.org/10.1089/mdr.1996.2.201.
111. Sadowska B, Cochard T, Poutrel B, Pytlos M, Bonar A, Gatkowska J, Rudnicka W, Polak J, Bielecki S, Siwinska-Golebiowska H, Rozalska B. 2001. Characterization ofStaphylococcus aureus strains from cystic fibro-sis patients by conventional and molecular typing. Acta Microbiol. Pol. 50:251-261.
112. Goss CH, Muhlebach MS. 2011. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J. Cyst. Fibros. 10:298-306. http://dx.doi.org/10.1016/j.jcf.2011.06.002.
113. 1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178:814-818. http://dx.doi.org/10.1164/rccm.200802-327OC.
114. Denis O, Nonhoff C, Byl B, Knoop C, Bobin-Dubreux S, Struelens MJ. 2002. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J. Antimicrob. Chemother. 50:383-391. http://dx.doi.org/10.1093/jac/dkf142.
115. Filleron A, Chiron R, Reverdy ME, Jean-Pierre H, Dumitrescu O, Aleyrangues L, Counil F, Jumas-Bilak E, Marchandin H. 2011. Staph-ylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients. J. Cyst. Fibros. 10:377-382. http://dx.doi.org/10.1016/j.jcf.2011.05.001.
116. Cafiso V, Bertuccio T, Spina D, Campanile F, Bongiorno D, Santagati M, Sciacca A, Sciuto C, Stefani S. 2010. Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 29:1277-1285. http://dx.doi.org/10.1007/s10096-010-1000-5.
117. Filleron A, Chiron R, Reverdy ME, Jean-Pierre H, Dumitrescu O, Aleyrangues L, Counil F, Jumas-Bilak E, Marchandin H. 2011. Staph-ylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients. J. Cyst. Fibros. 10:377-382. http://dx.doi.org/10.1016/j.jcf.2011.05.001.
118. Perry JD, Laine L, Hughes S, Nicholson A, Galloway A, Gould FK. 2008. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J. Antimi-crob. Chemother. 61:1057-1061. http://dx.doi.org/10.1093/jac/dkn081.
119. Morlin GL, Hedges DL, Smith AL, Burns JL. 1994. Accuracy and cost of antibiotic susceptibility testingof mixed morphotypes ofPseudomonas aeruginosa. J. Clin. Microbiol. 32:1027-1030.
120. Bar-Meir M, Jain M, McColley S, King J, Cullina J, Potter E, Powers C, Yogev R, Hauser AR. 2006. Heterogeneity in antibiotic susceptibilities of Pseudomonas aeruginosa respiratory isolates from individuals with cystic fibrosis. Chest 130:138S.
121. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. 2003. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 123:1495-1502. http://dx.doi.org/10.1378/chest.123.5.1495.
122. Hurley MN, Amin-Ariff AH, Bertenshaw C, Bhatt J, Smyth AR. 2012. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J. Cyst. Fibros. 11:288-192. http://dx.doi.org/10.1016/j.jcf.2012.02.006.
123. Wolter JM, Kotsiou G, McCormack JG. 1995. Mixed morphotype testing of Pseudomonas aeruginosa cultures from cystic fibrosis patients. J. Med. Microbiol. 42:220-234. http://dx.doi.org/10.1099/00222615-42-3-220.
124. O’Riordan TG. 2000. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. Respir. Care 45:836-845.
125. O’Riordan TG, Faris M. 1999. Inhaled antimicrobial therapy. Respir. Care N. Am. 5:617-631.
126. Yu X, Zipp GL, Davidson GWR. 1994. The effect of temperature and pH on the solubility of quinolone compounds: estimation of heat of fusion. Pharm. Res. 11:522-527. http://dx.doi.org/10.1023/A:1018910431216.
127. Bergström CAS, Norinder U, Luthman K, Artursson P. 2002. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm. Res. 19:182-188. http://dx.doi.org/10.1023/A:1014224900524.
128. Olivera ME, Manzo RH, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2011. Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. J. Pharm. Sci. 100:22-33. http://dx.doi.org/10.1002/jps.22259.
129. Bayer Germany AG. 1987. Ciproxin broad spectrum antibiotic, product monograph, E 22-897/849631. Bayer Germany AG, Leverkusen, Germany.
130. Surber MW, Bostian KA, Dudley MN, Rodny O, Griffith DC. January 2013. Aerosolized fluoroquinolones and uses thereof. US patent 8,357,696 B2.
131. Budavari S, O’Neil MJ, Heckelman PE, Kinneary JF (ed). 1996. The Merck index, 12th ed. Merck & Co, Inc, Whitehouse Station, NJ.
132. Wong JP, Cherwonogroszky JW, DiNinno VL, Dela-Cruz R, Saravol-atz EG. 1995. Liposome-encapsulated ciprofloxacin for the prevention and treatment of infectious diseases caused by intracellular pathogens, p 105-120. In Florence AT, Gregoriadis G (ed), Liposomes in biomedical applications. Harwood Academic Press, Amsterdam, Netherlands
133. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN. 2003. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 92:265-273. http://dx.doi.org/10.1016/S0168-3659(03)00358-4.
134. Conley J, Yang H, Wilson T, Blasetti K, DiNinno V, Schnell G, Wong JP. 1997. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice. Antimicrob. Agents Chemother. 41:1288-1292.
135. Bakker-Woudenberg IAJM, ten Kate MT, Guo L, Working P, Mouton JW. 2002. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob. Agents Chemother. 46:2575-2581. http://dx.doi.org/10.1128/AAC.46.8.2575-2581.2002.
136. Stass H, Dalhoff A. 2010. Ciprofloxacin inhale—a pharmacokinetic (PK)/pharmacodynamic (PD) rationale. Am. J. Respir. Crit. Care Med. 181:A1820.
137. Parkins MD, Elborn JS. 2011. Tobramycin inhalation powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev. Respir. Med. 5:609-622. http://dx.doi.org/10.1586/ers.11.56.
138. Geller DE, Weers J, Heuerding S. 2011. Development of an inhaled dry-powder formulation of tobramycin using PuloSphere technology. J. Aerosol Med. Pulm. Drug Deliv. 24:175-182. http://dx.doi.org/10.1089/jamp.2010.0855.
139. Forrest Laboratories, Inc. 2012. Colobreathe product monograph. Forrest Laboratories, Inc, New York, NY.
140. Anonymous. 2014. Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic fibrosis patients. Clinical Trials no. NCT01746095, last updated January 2014, last verified January 2014. https://ClinicalTrials.gov/.
141. MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, Kenney TF, Burns J., Baker WR. 2009. Antibacterial activities of a fosfomycin/ tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J. Antimicrob. Chemother. 64:829-836. http://dx.doi.org/10.1093/jac/dkp282.
142. Gilead Sciences, Inc. 2012. Cayston product monograph, control no. 152902. Gilead Sciences, Inc, Foster City, CA.
143. Döring G, Dalhoff A. 2013. Aerosolised levofloxacin in cystic fibrosis. Expert Opin. Orphan Drugs 1:549-556. http://dx.doi.org/10.1517/21678707.2013.820133.
144. Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, Smith AL. 1987. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob. Agents Chemother. 31:915-919. http://dx.doi.org/10.1128/AAC.31.6.915.
145. Bender SW, Dalhoff A, Shah PM, Strehl R, Posselt HG. 1986. Cipro-floxacin pharmacokinetics in patients with cystic fibrosis. Infection 14: 17-21. http://dx.doi.org/10.1007/BF01644804.
146. Smith MJ, White LO, Bowyer H, Willis J, Hosdon ME, Batten JC. 1986. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob. Agents Chemother. 30:614-616. http://dx.doi.org/10.1128/AAC.30.4.614.
147. Goldfarb J, Wormser GP, Inchiosa MA, Guideri G, Diaz M, Gandhi R, Goltzman C, Mascia AV. 1986. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J. Clin. Pharmacol. 26:222-236. http://dx.doi.org/10.1002/j.1552-4604.1986.tb02938.x.
148. Fabre D, Bressolle F, Gomeni R, Arich C, Lemesle F, Beziau H, Galtier M. 1991. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mu-cosa. Antimicrob. Agents Chemother. 35:2521-2525. http://dx.doi.org/10.1128/AAC.35.12.2521.
149. Stass H, Nagelschmitz J, Willmann S, Delesen H, Gupta A, Baumann S. 2013. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin. Drug Invest. 33:419-427. http://dx.doi.org/10.1007/s40261-013-0082-0.
150. Bruinenberg P, Blanchard JD, Cipolla DC, Dayton F, Mudumba S, Gonda I. 2010. Inhaled liposomal ciprofloxacin: once a day management respiratory infections. Respir. Drug Deliv. 1:73-82.
151. Fujita A, Miya T, Tanaka R, Hirayama S, Isaka H, Ono Y, Koshiishi Y, Goya T. 1999. Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint. Jpn. J. Antibiot. 52:661-666.
152. Gotfried MH, Danziger LH, Rodvold KA. 2001. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119:1114-1122. http://dx.doi.org/10.1378/chest.119.4.1114.
153. Capitano B, Mattoes HM, Shore E, O’Brien A, Braman S, Sutherland C, Nicolau DP. 2004. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125: 965-973. http://dx.doi.org/10.1378/chest.125.3.965.
154. Andrews JM, Honeybourne D, Jwevons G, Brenwald NP, Cunningham B, Wise R. 1997. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose inpatients undergoingfibre-optic bronchoscopy. J. Antimicrob. Chemother. 40:573-577. http://dx.doi.org/10.1093/jac/40.4.573.
155. Lee CKK, Boyle MP, Diener-West M, Brass-Ernst L, Noschese M, Zeitlin PL. 2007. Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest 131:796-802. http://dx.doi.org/10.1378/chest.06-1524.
156. Von Baum H, Böttcher S, Hoffmann H, Sonntag HG. 2001. Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery. J. Antimicrob. Chemother. 47:729-730.
157. Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, Dudley MN. 2011. Pharmacokinetics and safety of MP 376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agents Che-mother. 55:2636-2640. http://dx.doi.org/10.1128/AAC.01744-10.
158. Mombelli G, Coppens L, Thys JP, Klastersky J. 1981. Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion. Antimicrob. Agents Chemother. 19:72-75. http://dx.doi.org/10.1128/AAC.19.1.72.
159. Mombelli G. 1985. Aminoglycoside levels in bronchial secretions. Schweiz. Med. Wochenschr. 115:93-96.
160. Pennington JE, Reynolds HY. 1973. Tobramycin in bronchial secretions. Antimicrob. Agents Chemother. 4:299-301. http://dx.doi.org/10.1128/AAC.4.3.299.
161. Santre C, Georges H, Jacquier JM, Leroy O, Beuscart C, Buguin D, Beaucaire G. 1995. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrob. Agents Chemother. 39:264-267.
162. Tayman C, El-Attug MN, Adams E, van Schepdael A, Debeer A, Allegaert K, Smits A. 2011. Quantification of amikacin in bronchial epithelial lining fluid in neonates. Antimicrob. Agents Chemother. 55: 3990-3993. http://dx.doi.org/10.1128/AAC.00277-11.
163. Gilbert DN. 2000. Aminoglycosides, p 307-336. In Mandell GL, Bennett JE, Dolin R (ed), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, London, United Kingdom.
164. Touw D., Jacobs FAH, Brimicombe RW, Heijerman HGM, Bakker W, Breimer DD. 1997. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 41:184-187.
165. Le Conte P, Potel G, Peltier P, Horeau D, Caillon J, Juvin ME, Kergueris MF, Bugnon D, Baron D. 1993. Lung distribution and phar-macokinetics of aerosolized tobramycin. Am. J. Respir. Crit. Care Med. 147:1279-1282.
166. Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Preti M, Aryayev NL. 2007. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr. Drugs 9(Suppl 1): 11-20. http://dx.doi.org/10.2165/00148581-200709001-00003.
167. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW, Aerosolized Tobramycin Study Group. 1997. A comparison of peak sputum tobramycin concentrations in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 111: 955-962.
168. Geller DE, Pitlik WH, Nardella PA, Tracewell WG, Ramsey BW. 2002. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122:219-226. http://dx.doi.org/10.1378/chest.122.1.219.
169. Geller DE, Konstan M., Smith J, Noonberg SB, Conrad C. 2007. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharma-cokinetics and safety. Pediatr. Pulmonol. 42:307-313. http://dx.doi.org/10.1002/ppul.20594.
170. Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R. 2009. Pharma-cokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalationin cysticfibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother. 53:3847-3854. http://dx.doi.org/10.1128/AAC.00872-08.
171. Clancy JP, Dupont L, Konstan M., Billings J, Fustik S, Goss CH, Lymp JL, Minic P, Quiotter AL, Rubenstein RC, Young KR, Saiman L, Burns J., Govan JRW, Ramsey B, Gupta R. 2013. Phase II studies of nebulized ArikaceinCF patients withPseudomonas aeruginosa infection. Thorax 68:818-825. http://dx.doi.org/10.1136/thoraxjnl-2012-202230.
172. Vinks AA, von Rossem RN, Mathot RAA, Heijerman HGM, Mouton JW. 2007. Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob. Agents Chemother. 51: 3049-3055. http://dx.doi.org/10.1128/AAC.01522-06.
173. Boccazzi A, Langer M, Mandelli M, Ranzi AM, Urso R. 1989. The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients. J. Antimicrob. Chemother. 23:401-407. http://dx.doi.org/10.1093/jac/23.3.401.
174. Bechard DL, Hawkins SS, Dhruv R, Friedhoff LT. 1985. Penetration of aztreonam into human bronchial secretions. Antimicrob. Agents Che-mother. 27:263-264.
175. Mattie H. 1994. Clinical pharmacokinetics of aztreonam. Clin. Pharmaco-kinet. 26:99-106. http://dx.doi.org/10.2165/00003088-199426020-00003.
176. Gibson RL, Retsch-Bogart GZ, Oermann CM, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Markus R, Burns JL. 2006. Microbiology, safety, and pharmacokinetics of aztreo-nam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pul-monol. 41:656-665. http://dx.doi.org/10.1002/ppul.20429.
177. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy K., Montgomery AB, Cooper PJ. 2009. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 135: 1223-1232. http://dx.doi.org/10.1378/chest.08-1421.
178. Westerman EM, de Boer AH, Le Brun PPH, Touw D., Rodaan AC, Frijlink HW, Heijerman HGM. 2007. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J. Cyst. Fibros. 6:284-292. http://dx.doi.org/10.1016/j.jcf.2006.10.010.
179. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham Etherington DC, Turnidge J. 2003. Steady-state pharmacokinetics of intravenous colis-tin methanosulphonate in patients with cystic fibrosis. J. Antimicrob. Che-mother. 52:987-992. http://dx.doi.org/10.1093/jac/dkg468.
180. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Konigsbruggen S, Grasemann H. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57: 306-311. http://dx.doi.org/10.1093/jac/dki461.
181. Li J, Nation RL. 2006. Comment on: pharmacokinetics of inhaled colis-tin in patients with cystic fibrosis. J. Antimicrob. Chemother. 58:222-223. http://dx.doi.org/10.1093/jac/dkl169.
182. Markou N, Fousteri M, Markantonis SL, Boutzouka E, Tsigou E, Baltopoulo G. 2011. Colistin penetration in the alveolar lining fluid of critically ill patients treated with colistimethate sodium. Chest 139:232-233. http://dx.doi.org/10.1378/chest.10-1860.
183. Imberti R, Iotti GA, Cusato M, Regazzi M. 2011. Response to colistin penetration in the alveolar lining fluid of critically ill patients treated with colistimethate sodium. Chest 139:233-234. http://dx.doi.org/10.1378/chest.10-2107.
184. Cazzola M, Blasi F, Terzano C, Matera MG, Marsico DAS. 2002. Delivering antibacterials to the lungs. Am. J. Respir. Med. 1:261-272. http://dx.doi.org/10.1007/BF03256617.
185. 2 on the activity of antimicrobial agents in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 12:519-526. http://dx.doi.org/10.1007/BF01970957.
186. Barza M. 1992. Pharmacologic principles, p 147-153. In Gorbach SL, Bartlett JG, Blacklow N (ed), Infectious diseases. Saunders, Philadelphia, PA.
187. Gudmundsson A, Erlensdottir H, Gottfredsson M, Gudmundsson S. 1991. Impact of pH and cationic supplementation on in vitro postantibi-otic effect. Antimicrob. Agents Chemother. 35:2617-2624. http://dx.doi.org/10.1128/AAC.35.12.2617.
188. Dalhoff A, Schubert S, Ullmann U. 2005. Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolo-nes, macrolides, and a ketolide. Infection 33(Suppl 2):36-43. http://dx.doi.org/10.1007/s15010-005-8206-y.
189. Dalhoff A, Stubbings W, Schubert S. 2011. Comparative in vitro activ-itiesofthe novel antibacterialfinafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine. Antimicrob. Agents Chemother. 55:1814-1818. http://dx.doi.org/10.1128/AAC.00886-10.
190. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter baumanniiassociated with mutationsinthe PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634. http://dx.doi.org/10.1128/AAC.00284-09.
191. Anonymous. 2007. Azactam (aztreonam) injection, powder, for solution, product information. Bristol-Myers Squibb Co, New York, NY.
192. Niederman MS. 2003. Antibiotic therapy in critical illness. ACCP Crit. Care Rev. 2003:473-480.
193. Vaudaux P. 1981. Peripheral inactivation of gentamicin. J. Antimicrob. Chemother. 8(Suppl A):17-25.
194. Waldvogel FA. 1984. Future perspectives of aminoglycoside therapy. J. Antimicrob. Chemother. 13(Suppl A):73-78.
195. Shen LL, Baranowski J, Pernet AG. 1989. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry 28:3879-3885. http://dx.doi.org/10.1021/bi00435a038.
196. Noble CG, Barnard FM, Maxwell A. 2003. Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction with the gyrase-DNA complex. Antimicrob. Agents Che-mother. 47:854-862 http://dx.doi.org/10.1128/AAC.47.3.854-862.2003.
197. Edlund C, Lindqvist L, Nord CE. 1988. Norfloxacin binds to human fecal material. Antimicrob. Agents Chemother. 32:1869-1874 http://dx.doi.org/10.1128/AAC.32.12.1869.
198. Kirby AE, Garner K, Levin BR. 2012. The relative contribution of physical structure and cell density to the antibiotic susceptibility of bacteria in biofilms. Antimicrob. Agents Chemother. 56:2967-2975 http://dx.doi.org/10.1128/AAC.06480-11.
199. Dalhoff A, Ullmann U. 1990. Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur. J. Clin. Microbiol. Infect. Dis. 9:479-487. http://dx.doi.org/10.1007/BF01964287.
200. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12. http://dx.doi.org/10.1086/516284.
201. Drusano G. 2004. Antimicrobial pharmacodynamics: critical interactions of “bug and drug.” Nat. Rev. Microbiol. 2:289-300. http://dx.doi.org/10.1038/nrmicro862.
202. Ambrose P, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin. Infect. Dis. 44:79-86. http://dx.doi.org/10.1086/510079.
203. Dalhoff A, Ambrose PG, Mouton JW. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37:296-305. http://dx.doi.org/10.1007/s15010-009-7108-9.
204. Mouton JW, Ambrose PG, Canton R, Drusano G., Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J. 2011. Conserving antibiotics for the future: new ways to use old and new drugs from a phar-macokinetic and pharmacodynamic perspective. Drug Resist. Updat. 14: 107-117. http://dx.doi.org/10.1016/j.drup.2011.02.005.
205. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132:761-765.
206. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081. http://dx.doi.org/10.1128/AAC.37.5.1073.
207. Hyatt JM, Nix DE, Schentag JJ. 1994. Pharmacokinetic and pharmaco-dynamic activities of ciprofloxacin against strains of Streptococcus pneu-moniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs were similar. Antimicrob. Agents Chemother. 38:2730-2727. http://dx.doi.org/10.1128/AAC.38.12.2730.
208. Zelenitsky SA, Harding GKM, Sun S, Zbhi K, Ariano RE. 2003. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J. Antimcrob. Chemother. 52:668-674. http://dx.doi.org/10.1093/jac/dkg403.
209. Zelenitsky S, Ariano R, Harding G, Forrest A. 2005. Evaluating ciprofloxa-cin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob. Agents Chemother. 49:4009-4014. http://dx.doi.org/10.1128/AAC.49.10.4009-4014.2005.
210. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. 1996. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolones antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacody-namic model. Antimicrob. Agents Chemother. 40:627-632.
211. Pea F, Poz D, Viale P, Pavan F, Furlanut M. 2006. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital? A TDM-based retrospective perspective. J. Antimicrob. Chemother. 58:380-386. http://dx.doi.org/10.1093/jac/dkl226.
212. Kuti JL, Nightingale CH, Nicolau DP. 2004. Optimizing pharmacody-namic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob. Agents Chemother. 48:2464-2470. http://dx.doi.org/10.1128/AAC.48.7.2464-2470.2004.
213. Szalek E, Kaminska A, Gozdzik-Spychalska J, Grezkowiak E, Batura-Gabryel H. 2011. The PK/PD index (Cmax/MIC) for ciprofloxacin in patients with cystic fibrosis. Acta Pol. Pharm. 68:777-783.
214. Stockmann C, Sherwin CMT, Zobell JT, Young DC, Waters CD, Spigarelli MG, Ampofo K. 2013. Optimization of anti-pseudomonal antibiotics for cysticfibrosis pulmonary exacerbations. III. Fluoroquino-lones. Pediatr. Pulmonol. 48:211-220. http://dx.doi.org/10.1002/ppul.22667.
215. King P, Lomovskaya O, Griffith DC, Burns J., Dudley MN. 2010. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob. Agents Chemother. 54:143-148. http://dx.doi.org/10.1128/AAC.00248-09.
216. Sabet M, Miller CE, Nolan TG, Seneko-Effenberger K, Dudley MN, Griffith DC. 2009. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aerugi-nosa. Antimicrob. Agents Chemother. 53:3923-3928. http://dx.doi.org/10.1128/AAC.00268-09.
217. Moore RD, Lietman PS, Smith CR. 1987. Clinical response to amino-glycoside therapy: importance of the ratio of peak concentration to minimum inhibitory concentration. J. Infect. Dis. 155:93-99. http://dx.doi.org/10.1093/infdis/155.1.93.
218. Kashuba ADM, Nafziger AN, Drusano G., Bertino JS. 1999. Optimizing aminoglycoside therapy for nosocomial pneumonia causedbyGram-negative bacteria. Antimicrob. Agents Chemother. 43:623-629.
219. Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. 2013. Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Antimicrob. Agents Che-mother. 57:5175-5177. http://dx.doi.org/10.1128/AAC.00539-13.
220. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. 2005. Pharmaco-dynamics of tobramycin in patients with cystic fibrosis. Diagn. Micro-biol. Infect. Dis. 52:123-127. http://dx.doi.org/10.1016/j.diagmicrobio.2005.02.011.
221. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. 2006. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice daily tobramycin but more resistance development? J. Antimicrob. Chemother. 58:822-829. http://dx.doi.org/10.1093/jac/dkl328.
222. Dupont L, Minic P, Mazurek H, Solyom E, Feketova A, Csiszer E, Gupta R. 2008. A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Cyst. Fibros. 7:S26. http://dx.doi.org/10.1016/S1569-1993(08)60099-5.
223. Beringer P., Vinks AATMM, Jelliffe RW, Shapiro BJ. 2000. Pharma-cokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob. Agents Chemother. 44:809-813. http://dx.doi.org/10.1128/AAC.44.4.809-813.2000.
224. Horrevorts AM, Degener JE, Dzoljic-Dailovic G, Michel MF, Kerrebin KF, Driessen O, Hermans J. 1985. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval. Chest 88:260-264.
225. Byl B, Baran D, Jacobs F, Herschuelz A, Thys JP. 2001. Serum phar-macokinetics and sputum penetration of amikacin 30 mg/kg once daily and ceftazidime 200 mg/kg/day as acontinuous infusion incystic fibrosis patients. J. Antimicrob. Chemother. 48:325-327. http://dx.doi.org/10.1093/jac/48.2.325.
226. Lodise TP, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. 2004. Pharmacokinetic profiling of piperacillin in the presence of tazo-bactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48: 4718-4724. http://dx.doi.org/10.1128/AAC.48.12.4718-4724.2004.
227. Bulitta JB, Dufull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano G., Sörgel F. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibro-sis patients and healthy volunteers. Antimicrob. Agents Chemother. 51: 2497-2507. http://dx.doi.org/10.1128/AAC.01477-06.
228. Bulitta JB, Landersdorfer CB, Hüttner SJ, Drusano G., Kinzig M, Holzgrabe U, Stephan U, Sörgel F. 2010. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 54:1275-1282. http://dx.doi.org/10.1128/AAC.00936-09.
229. Bergen PJ, Li J, Nation RL, Turnidge J., Coulthard K, Milne RW. 2008. Comparison of once, twice, and thrice daily-dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomo-nas aeruginosa in an in vitro pharmacodynamic model. J. Antimicrob. Chemother. 61:636-642. http://dx.doi.org/10.1093/jac/dkm511.
230. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL. 2010. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob. Agents Chemother. 54:3783-3789. http://dx.doi.org/10.1128/AAC.00903-09.
231. Dudhani RV, Turnidge J., Coulthard K, Milne RW, Rayner CR, Li J, Nation RL. 2010. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54: 1117-1124. http://dx.doi.org/10.1128/AAC.01114-09.
232. Mouton JW, Hollander JG, Horrevorts AM. 1993. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J. Antimicrob. Chemother. 31:919-926. http://dx.doi.org/10.1093/jac/31.6.919.
233. Hoffman LR, Richardson AR, Houston LS, Kulasekara HD, Martens-Habbena W, Klausen J, Burns J., Stahl DA, Hasset DJ, Fang FC, Miller SI. 2010. Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway. PLoS Pathog. 6:712. http://dx.doi.org/10.1371/journal.ppat.1000712.
234. Driffield K, Miller K, Bostock JM, O’Neill AJ, Chopra I. 2008. Increased mutability of Pseudomonas aeruginosa in biofilms. J.Antimicrob. Chemother. 61:1053-1056. http://dx.doi.org/10.1093/jac/dkn044.
235. Lewis K. 2010. Persister cells. Annu. Rev. Microbiol. 64:357-372. http://dx.doi.org/10.1146/annurev.micro.112408.134306.
236. Lewis K. 2012. Persister cells: molecular mechanisms related to antibiotic resistance, p 121-133. In Coates ARM (ed), Antibiotic resistance. Handbook of experimental pharmacology, vol 211. Springer-Verlag, Berlin, Germany.
237. Cohen NR, Lobritz MA, Collins JJ. 2013. Microbial persistence and the roadtodrug resistance. Cell Host Microbe 13:632-642. http://dx.doi.org/10.1016/j.chom.2013.05.009.
238. Fitzgerald JR, Sturdevant DE, Mackie SM, Gill SR, Musser JM. 2001. Evolutionary genomics of Staphylococcus aureus: insights into the origin of methicillin-resistant strains and the toxic shock syndrome epidemic. Proc. Natl. Acad. Sci. U. S. A. 98:8821-8826. http://dx.doi.org/10.1073/pnas.161098098.
239. Macia MD, Borelli N, Segura M, Gomez C, Perez JL, Oliver A. 2006. Efficacy and potential for resistance selection of antipseudomonal treatments inamouse model oflung infection byhypermutablePseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:975-983. http://dx.doi.org/10.1128/AAC.50.3.975-983.2006.
240. Ferroni A, Guillemot D, Moumile K, Bernede C, Le Bourgeois M, Waernessyckle S, Descamps P, Sermet-Gaudelus I, Lenoir G, Berche P, Taddei F. 2009. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory functionincysticfibrosis. Pediatr. Pulmonol. 44:820-825. http://dx.doi.org/10.1002/ppul.21076.
241. Nair CG, Chao C, Ryall B, Williams HD. 2013. Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa. Lett. Appl. Microbiol. 56:149-154. http://dx.doi.org/10.1111/lam.12032.
242. Macia MD, Perez JL, Molin S, Oliver A. 2011. Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. Antimicrob. Agents Chemother. 55:5230-5237. http://dx.doi.org/10.1128/AAC.00617-11.
243. Blaser J, Stone BB, Groner MC, Zinner SH. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060. http://dx.doi.org/10.1128/AAC.31.7.1054.
244. Zinner SH, Gilbert D, Greer K, Portnoy YA, Firsov AA. 2013. Concentration-resistance relationship with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J. Antimicrob. Chemother. 68:881-887. http://dx.doi.org/10.1093/jac/dks463.
245. Molina A, Del Campo R, Maiz L, Morosini MI, Lamas A, Baquero F, Canton R. 2008. High prevalence in cystic fibrosis patients of multire-sistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. J. Antimicrob. Chemother. 62:961-967. http://dx.doi.org/10.1093/jac/dkn302.
246. Goss CH, Muhlebach MS. 2011. Review: Staphylococcus aureus in cystic fibrosis. J. Cyst. Fibros. 10:298-306. http://dx.doi.org/10.1016/j.jcf.2011.06.002.
247. Jevons MP. 1961. “Celbenin”-resistant staphylococci. Br. Med. J. i:124-125. http://dx.doi.org/10.1136/bmj.1.5219.124.
248. Utsui Y, Yokota T. 1985. Role of an altered penicillin-binding protein in methicillin-and cephem-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 28:397-403. http://dx.doi.org/10.1128/AAC.28.3.397.
249. Berger-Bächi B, Rohrer S. 2002. Factors influencing methicillin resistance in staphylococci. Arch. Microbiol. 178:165-171. http://dx.doi.org/10.1007/s00203-002-0436-0.
250. Deresinski S. 2005. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40: 562-573. http://dx.doi.org/10.1086/427701.
251. Yamamoto T, Nishiyama A, Takano T, Yabe S, Higuchi W, Razvina O, Shi D. 2010. Community-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug-resistance. J. Infect. Chemother. 16:225-254. http://dx.doi.org/10.1007/s10156-010-0045-9.
252. Kuhl SA, Pattee PA, Baldwin JN. 1978. Chromosomal map location of the methicillin resistance determinant in Staphylococcus aureus. J. Bacteriol. 135:460-465.
253. Pattee PA, Lee HC, Bannantine JP. 1990. Genetic and physical mapping of the chromosome of Staphylococcus aureus, p 41-58. In Novik RP (ed), Molecular biology of the staphylococci. VCH Publishers, New York, NY.
254. Ito T, Katayama Y, Hiramatsu K. 1999. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315. Antimicrob. Agents Chemother. 43:1449-1458.
255. Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM. 2001. Selection of high-level oxacillin resistance in heteroresistant Staph ylococcus aureus by fluoroquinolone exposure. J. Antimcrob. Che mother. 48:375-381. http://dx.doi.org/10.1093/jac/48.3.375.
256. Dalhoff A, Schubert S. 2010. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones. Int. J. Antimicrob. Agents 36:216-221. http://dx.doi.org/10.1016/j.ijantimicag.2010.04.014.
257. Ubukata K, Nonoguchi R, Matsuhashi M, Song MD, Konno M. 1989. Restriction map of the regions coding for methicillin and tobramycin resistances on chromosomal DNA in methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 33:1624-1626. http://dx.doi.org/10.1128/AAC.33.9.1624.
258. Chambers HF. 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10:781-191.
259. Ida T, Okamoto R, Nonoyama M, Irinoda K, Kurazono M, Inoue M. 2002. Antagonism between aminoglycosides and [3-lactams in a methi cillin-resistant Staphylococcus aureus isolate involves induction of an aminoglycoside-modifying enzyme. Antimicrob. Agents Chemother. 46: 1516-1521. http://dx.doi.org/10.1128/AAC.46.5.1516-1521.2002.
260. Hoffman LR, Deziel E, D’Argenio DA, Lepine F, Emerson J, Mc-Namara S, Gibson RL, Ramsey BW, Miller SI. 2006. Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 103: 19890-19895. http://dx.doi.org/10.1073/pnas.0606756104.
261. Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, Houston LS, Rogers GB, March P, Prehar K, Pope CE, Blackledge M, Deziel E, Bruce KD, Ramsey BW, Gibson RL, Burns J., Hoffman LR. 2013. Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin. Infect. Dis. 57:384-391. http://dx.doi.org/10.1093/cid/cit270.
262. Biswas L, Biswas R, Schlag M, Bertram R, Gotz F. 2009. Small-colony variant selection as a survival strategy for Staphylococcus aureus in the presence of Pseudomonas aeruginosa. Appl. Environ. Microbiol. 75: 6910-1912. http://dx.doi.org/10.1128/AEM.01211-09.
263. Idelevich EA, Kriegskorte A, Stubbings W, Kahl BC, Peters G, Becker K. 2011. Comparative in vitro activity of finafloxacin against staphylo-cocci displaying normal and small colony variant phenotypes. J. Antimi-crob. Chemother. 66:2809-2813. http://dx.doi.org/10.1093/jac/dkr393.
264. Schmitz FJ, von Eiff C, Gondolf M, Fluit AC, Verhoef J, Peters G, Hadding U, Heinz HP, Jones ME. 1999. Staphylococcus aureus small colony variants: rate of selection and MIC values compared to wild-type strains, using ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin. Clin. Microbiol. Infect. 5:376-378. http://dx.doi.org/10.1111/j.1469-0691.1999.tb00158.x.
265. von Eiff C, Peters G. 1999. Comparative in-vitro activities of moxifloxa-cin, trovafloxacin, quinopristin/dalfopristin and linezolid against staph-ylococci. J. Antimicrob. Chemother. 43:569-573. http://dx.doi.org/10.1093/jac/43.4.569.
266. McAdam PR, Holmes A, Templeton KE, Fitzgerald JR. 2011. Adaptive evolution of Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient. PLoS One 6:e24301 http://dx.doi.org/10.1371/journal.pone.0024301.
267. Trong HN, Prunier AL, Leclerq R. 2005. Hypermutable fluoroquin-olone-resistant clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:2098-2101. http://dx.doi.org/10.1128/AAC.49.5.2098-2101.2005.
268. Schaaf F, Bierbaum G, Baumert N, Bartmann P, Sahl HG. 2003. Mutations are involved in emergence of aminoglycoside-induced small colony variants of Staphylococcus aureus. Int. J. Med. Microbiol. 293: 427-435. http://dx.doi.org/10.1078/1438-4221-00282.
269. Roman F, Canton R, Perez-Vazquez M, Baquero F, Campos J. 2004. Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hyper-mutable strains. J. Clin. Microbiol. 42:1450-1459. http://dx.doi.org/10.1128/JCM.42.4.1450-1459.2004.
270. Watson ME Jr, Burns J., Smith AL. 2004. Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150:2947-2958. http://dx.doi.org/10.1099/mic.0.27230-0.
271. Georgiou M, Minoz R, Roman F, Canton R, Gomez-Lus R, Campos J, de la Campa AG. 1996. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. An-timicrob. Agents Chemother. 40:1741-1744.
272. Gould IM, Forges KJ, Gordon GS. 1994. Quinolone resistant Haemo-philus influenzae. J. Antimicrob. Chemother. 33:187-188. http://dx.doi.org/10.1093/jac/33.1.187.
273. Barriere S, Hindler J. 1993. Ciprofloxacin-resistant Haemophilus influ-enzae infection in a patient with chronic lung disease. Ann. Pharmaco-ther. 27:309-310.
274. Roberts MC, Soge OO, No DB. 2011. Characterization of macrolide resistance genes in Haemophilus influenzae isolated from children with cystic fibrosis. J. Antimicrob. Chemother. 66:100-104. http://dx.doi.org/10.1093/jac/dkq425.
275. Phaff SJ, Tiddens HA, Verbrugh H, Ott A. 2006. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J. Antimicrob. Chemother. 57: 741-746. http://dx.doi.org/10.1093/jac/dkl014.
276. Southern KW, Barker PM, Solis-Moya A, Patel L. 2012. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 11: CD002203. http://dx.doi.org/10.1002/14651858.CD002203.pub4.
277. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpern JL, van der Ent CK. 2007. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr. Infect. Dis. J. 26:8-12. http://dx.doi.org/10.1097/01.inf.0000247109.44249.ac.
278. Rolain JM, Francois P, Hernandez D, Bittar F, Richet H, Fournous G, Mattenberger Y, Bosdure E, Stremler N, Dubus JC, Sarles J, Reynaud-Gaubert M, Boniface S, Schrenzel J, Raoult D. 2009. Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage. Biol. Direct 4:1. http://dx.doi.org/10.1186/1745-6150-4-1.
279. Rolain JM, Fancella L, Desnues C, Raoult D. 2011. Bacteriophages as vehicles of the resistome in cystic fibrosis. J. Antimicrob. Chemother. 66:2444-2447. http://dx.doi.org/10.1093/jac/dkr318.
280. Anonymous. 2012. Study to evaluate the safety and efficacy of cipro-floxacin (inhaled) in patients with cystic fibrosis. Clinical Trials no. NCT00645788, last update May 2012. https://ClinicalTrials.gov/.
281. Bilton D, Bruinenberg P, Otulana B, Blanchard J, DeSoyza A, Serisier D. 2009. Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in CF and non-CF bron-chiectasis. Am. J. Respir. Crit. Care Med. 179:A3214.
282. Bender SW, Shah PM, Strehl R, Posselt HG. 1985. Distribution kinetics of ciprofloxacin for evaluation of therapeutic efficacy in Pseudomonas aeruginosa bronchopneumonia in cystic fibrosis patients, p 1662-1663. In Ishigami J (ed), Progress of the International Congress of Chemotherapy, Kyoto, Japan, 1985. Recent advances in chemotherapy, antimicrobial section 2. University of Tokyo Press, Tokyo, Japan.
283. Bender SW, Posselt HG, Wönne R, Stöver B, Strehl R, Shah PM, Bauernfeind A. 1987.Ciprofloxacin treatment of patients with cystic fibrosis and Pseudomonas bronchopneumonia, p 272-278. In Weuta H, Neu HC (ed), First International Ciprofloxacin Workshop: Leverkusen, 6-8 November 1985: proceedings. Current practice, no. 34, excerpta medica. Elsevier Science Ltd, New York, NY.
284. Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ. 2011. Levofloxacin inhalation solution (MP-376) in patients with cystic fibro-sis with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 183: 1510-1516. http://dx.doi.org/10.1164/rccm.201008-1293OC.
285. Anonymous. 2012. Safety, tolerability and efficacy of MP-376 given for 28 days to cystic fibrosis (CF) patients. Clinical Trials no. NCT00677365, last update May 2012. https://ClinicalTrials.gov/.
286. Southern KW, Barker PM. 2004. Azithromycin for cystic fibrosis. Eur. Respir. J. 24:834-838. http://dx.doi.org/10.1183/09031936.04.00084304.
287. Cheer SM, Waugh J, Noble S. 2003. Inhaled tobramycin (TOBI): a review ofits use inthe management ofP. aeruginosainfectionsinpatients with cystic fibrosis. Drugs 63:2501-2520. http://dx.doi.org/10.2165/00003495-200363220-00015.
288. Galeva I, Konstan M., Higgins M, Angyalosi G, Brockhaus F, Piggott S, Thomas K, Chuchalin AG. 2013. Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial. Curr. Med. Res. Opin. 29:947-956. http://dx.doi.org/10.1185/03007995.2013.805122.
289. Konstan M., Geller DE, Minic P, Brockhaus F, Zhang G. 2011. Tobramycin inhalation powder for P. aeruginosainfection incysticfibro-sis: the EVOLVE trial. Pediatr. Pulmonol. 46:230-238. http://dx.doi.org/10.1002/ppul.21356.
290. Konstan M., Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, Zhang J, Angyalosi EH, Geller DE. 2011. Safety, efficacy and convenience of tobramycin in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros. 10:54-61. http://dx.doi.org/10.1016/j.jcf.2010.10.003.
291. Lam J, Vaughan S, Parkins MD. 2013. Tobramycin inhalation powder (TIP): an efficient treatment strategy for the management of chronic Pseudomonas aeruginosa infection cystic fibrosis. Clin. Med. Insights Circ. Respir. Pulm. Med. 7:61-77. http://dx.doi.org/10.4137/CCRPM.S10592.
292. European Medicines Agency. 2011. Assessment report TOBI podhaler. Procedure no. EMEA/H/C/002155. European Medicines Agency, London, United Kingdom.
293. Australian Government Department of Health. 2013. Tobramycin powder for inhalation, capsules 28 mg, TobiPodhaler—March 2013. Public summary report. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meeting/psd/2013-03/tobramycin.
294. Hodson ME, Gallagher CG, Govan JRW. 2002. A randomized clinical trial of nebulized tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 20:658-664. http://dx.doi.org/10.1183/09031936.02.00248102.
295. Bilton D, Pressler T, Fajac I, Clancy JP, Minic OP, Cipolli M, LaRosa M, Galeva I, Sole A, Staab D, Dupont L, Goss CH, Hamblett N, Quittner A, Ramsey B, Gupta R, Konstan M. 2013. Phase 3 efficacy and safety data from randomized multicenter studies of liposomal amikacin for inhalation (Arikace) compared with TOBI in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa, abstr 235. Abstr. 27th N. Am. Cyst. Fibros. Conf. Cystic Fibrosis Foundation, Bethesda, MD.
296. Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeville GA, Sardet A, Deschildre A, Druon D, Arrouet-Lagande C. 1998. Efficacy, tolerance, and pharmacodynamics of once daily tobramycin for Pseudomo-nas exacerbations in cystic fibrosis. Arch. Dis. Child. 78:536-539. http://dx.doi.org/10.1136/adc.78.6.536.
297. Smyth AR, Bhatt J. 2014. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst. Rev. 2:CD002009. http://dx.doi.org/10.1002/14651858.CD002009.pub5.
298. Prescott WA, Nagel JL. 2010. Extended-interval once-daily dosing of aminoglycosides inadult and pediatric patients with cystic fibrosis. Phar-macotherapy 30:95-108. http://dx.doi.org/10.1592/phco.30.1.95.
299. Vic P, Ategbo S, Turck D, Husson MO, Tassin E, Loeuille GA, Deschildre A, Druon D, Elian JC, Arrouet-Lagandre C, Farriaux JP. 1996. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur. J. Pediatr. 155:948-953. http://dx.doi.org/10.1007/BF02282885.
300. Elborn JS, Henig NR. 2010. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine. Expert Opin. Phramacother. 11:1373-1385. http://dx.doi.org/10.1517/14656566.2010.482102.
301. Kirkby S, Novak K, McCoy K. 2011. Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis:an evidence-based review. Core Evid. 6:59-66. http://dx.doi.org/10.2147/CE.S11181.
302. Pesaturo KA, Horton ER, Belliveau P. 2012. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes. Ann. Pharmaco-ther. 46:1076-1085. http://dx.doi.org/10.1345/aph.1Q653.
303. Retsch-Bogart GZ, Burns J., Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL. 2008. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pedi-atr. Pulmonol. 43:47-58. http://dx.doi.org/10.1002/ppul.20736.
304. Anonymous. 2011. International safety and efficacy study of aztreonam for inhalation solution (AZLI) in cystic fibrosis patients with P. aerugi-nosa (AIR-CF1). Clinical Trials no. NCT00112359, last updated March 2011, last verified March 2011. https://ClinicalTrials.gov/.
305. McCoy K., Quittner AL, Oermann C, Gibson RL, Retsch-Bogart GZ, Montgomery AB. 2008. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178:921-928. http://dx.doi.org/10.1164/rccm.200712-1804OC.
306. Anonymous. 2011. Safety and efficacy of aztreonam for inhalation solution (AZLI)incysticfibrosis patients withP. aeruginosa(AIR-CF2). Clinical Trials no. NCT00104520, last updated February 2011, last verified September 2010. https://ClinicalTrials.gov/.
307. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy K., Montgomery AB. 2010. An 18 month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine incystic fibrosis. Pediatr. Pulmonol. 45:1121-1134. http://dx.doi.org/10.1002/ppul.21301.
308. Anonymous. 2011. Safety and efficacy study of aztreonam for inhalation solution (AZLI) in cysticfibrosis (CF) patients with Pseudomonas aerugi-nosa (PA) (AIR-CF3). Clinical Trials no. NCT00128492, last updated May 2011, last verified May 2011. https://ClinicalTrials.gov/.
309. Wainwright CE, Quittner AL, Geller DE, Nakamura C, Woolridge JL, Gibson RL, Lewis S, Montgomery AB. 2011. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J. Cyst. Fibros. 10:234-242. http://dx.doi.org/10.1016/j.jcf.2011.02.007.
310. Anonymous. 2010. Safety and efficacy study of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung disease, and P. aeruginosa (AIR-CF4). Clinical Trials no. NCT00712166, last updated November 2010, last verified November 2010. https://ClinicalTrials.gov/.
311. Anonymous. 2011. Aztreonam for inhalation solution vs tobramycin inhalation solution in patients with cystic fibrosis & P. aeruginosa. Clinical Trials no. NCT00757237, last updated June 2011, last verified June 2011. https://ClinicalTrials.gov/.
312. Bosso JA, Black PG. 1988. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbation of cystic fibrosis. Pediatr. Infect. Dis. J. 7:171-175. http://dx.doi.org/10.1097/00006454-198803000-00008.
313. Beringer P. 2001. The clinical use of colistin in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 7:434-440. http://dx.doi.org/10.1097/00063198-200111000-00013.
314. Das RR, Kabra SK, Singh M. 2013. Treatment of Pseudomonas aerugi-nosa and Staphylococcus aureus bronchopulmonary infection in patients with cystic fibrosis. ScientificWorldJournal 2013:645653. http://dx.doi.org/10.1155/2013/645653.
315. Li J, Nation RI, Turnidge J., Milne RW, Coulthard K, Rayner CR, Patersen DI. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601. http://dx.doi.org/10.1016/S1473-3099(06)70580-1.
316. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. 2006. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin. Med. Res. 4:138-146. http://dx.doi.org/10.3121/cmr.4.2.138.
317. Michalopoulos A, Papadakis E. 2010. Inhaled anti-infective agents: emphasis on colistin. Infection 38:81-88. http://dx.doi.org/10.1007/s15010-009-9148-6.
318. Schuster A, Haliburn C, Döring G, Goldman MH, Freedom Study Group. 2013. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomized study. Thorax 68:344-350. http://dx.doi.org/10.1136/thoraxjnl-2012-202059.
319. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. 1987. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseu-domonas aeruginosa lung infection. J. Antimicrob. Chemother. 19:831-838. http://dx.doi.org/10.1093/jac/19.6.831.
320. Govan JRW. 2002. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis. J. Cyst. Fibros. 1(Suppl 2): 203-208. http://dx.doi.org/10.1016/S1569-1993(02)00005-X.
321. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, Gore EJ, Redding GJ. 1989. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr. Pul-monol. 7:265-271. http://dx.doi.org/10.1002/ppul.1950070413.
322. McLaughlin FJ, Matthews WJ, Strieder DJ, Sullivan B, Taneja A, Murphy P, Goldmann DA. 1983. Clinical and bacteriological response to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin and azlocillin-placebo. J. Infect. Dis. 147:559-567. http://dx.doi.org/10.1093/infdis/147.3.559.
323. Ledson MJ, Gallaghar MJ, Cowerthwaite C, Convey RP, Walshaw MJ. 1998. Four years’ experience of intravenous colomycin in an adult cystic fibrosis unit. Eur. Respir. J. 12:592-594. http://dx.doi.org/10.1183/09031936.98.12030592.
324. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. 1997. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 52:987-993. http://dx.doi.org/10.1136/thx.52.11.987.
325. Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT, Henry MM, Leigh MW. 2010. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatr. Pulmonol. 45:281-290. http://dx.doi.org/10.1002/ppul.21176.
326. Labiris NRC, Holbrook AM, Chrystyn H, MacLeod SM, Newhouse MT. 1999. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am. J. Respir. Crit. Care Med. 160:1711-1716. http://dx.doi.org/10.1164/ajrccm.160.5.9810080.
327. Labro MT. 2000. Interference of antibacterial agents with phagocyte functions: immunomodulation or “immuno-fairy tales”? Clin. Microbiol. Rev. 13:615-650. http://dx.doi.org/10.1128/CMR.13.4.615-650.2000.
328. Dalhoff A, Shalit I. 2003. Immunomodulatory effects of quinolones. Lancet Infect. Dis. 3:359-371. http://dx.doi.org/10.1016/S1473-3099(03)00658-3.
329. Dalhoff A. 2005. Immunomodulatory activities of fluoroquinolones. Infection 33(Suppl2):55-70. http://dx.doi.org/10.1007/s15010-005-8209-8.
330. Rubin BK, Henke MO, Dalhoff A. 2005. Anti-inflammatory properties of antibiotics other than macrolides, p 247-268. In Rubin BK, Tamaoki J (ed), Antibiotics as anti-inflammatory and immunomodulatory agents. Birkhäuser Verlag, Basel, Switzerland.
331. Rubin BK, Henke MO. 2004. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125:70S-78S. http://dx.doi.org/10.1378/chest.125.2_suppl.70S.
332. Sharma S, Jaffe A, Dixon G. 2007. Immunomodulatory effects of mac-rolide antibiotics in respiratory disease. Therapeutic implications for asthma and cystic fibrosis. Pediatr. Drugs 9:107-118.
333. Brooks BM, Thomas AL, Coleman JW. 2003. Benzylpenicillin differentially conjugates to IFN-gamma, TNF-alpha, Il-1(3,Il-4 and Il-13 but selectively reduces IFN-gamma activity. Clin. Exp. Immunol. 131:268-274. http://dx.doi.org/10.1046/j.1365-2249.2003.02069.x.
334. Brooks BM, Flanagan BF, Thomas AL, Coleman JW. 2001. Penicillin conjugates to interferon-gamma and reduces its activity: a novel drug-cytokine interaction. Biochim. Biophys. Res. Commun. 288:1175-1181. http://dx.doi.org/10.1006/bbrc.2001.5896.
335. Brooks BM, Hart CA, Coleman JW. 2005. Differential effects of (3-lac-tams on human IFN-gamma activity. J. Antimicrob. Chemother. 56: 1122-1125. http://dx.doi.org/10.1093/jac/dki373.
336. Derichs N. 2013. Targeting a genetic defect: cystic fibrosis transmem-brane conductance regulator modulators in cystic fibrosis. Eur. Respir. Rev. 22:58-65. http://dx.doi.org/10.1183/09059180.00008412.
337. Wilschanski M. 2013. Novel therapeutic approaches for cystic fibrosis. Discov. Med. 15:127-133.
338. Gorini L, Kataja E. 1964. Phenotypic repair by streptomycin of defective genotypes in E. coli. Proc. Natl. Acad. Sci. U. S. A. 51:487-493. http://dx.doi.org/10.1073/pnas.51.3.487.
339. Wilschanski M, Famini C, Blau Rivlin HJ, Augarten A, Avital A, Kerem B, Kerem E. 2000. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am. J. Respir. Crit. Care Med. 161:860-865. http://dx.doi.org/10.1164/ajrccm.161.3.9904116.
340. Howard M, Frizzelli RA, Bedwell DM. 1996. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2:467-469. http://dx.doi.org/10.1038/nm0496-467.
341. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E. 2003. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349:1433-1441. http://dx.doi.org/10.1056/NEJMoa022170.
342. Clancy JP, Bebök Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, Lyrene R, Sorscher EJ, Bedwell DM. 2001. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 163:1683-1692. http://dx.doi.org/10.1164/ajrccm.163.7.2004001.
343. Sermet-Gaudelus I, Renouil M, Fajac A, Bidou L, Parbaille B, Pierrot S, Davy N, Bismuth E, Reinert P, Lenoir G, Lesure JF, Rousset JP, Edelman A. 2007. In vitro prediction of stop codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med. 5:5. http://dx.doi.org/10.1186/1741-7015-5-5.
344. Davies J, Spiegelman GB, Yim G. 2006. The world of subinhibitory antibiotic concentrations. Curr. Opin. Microbiol. 9:445-453. http://dx.doi.org/10.1016/j.mib.2006.08.006.
345. Duan K, Dammel C, Stein J, Rabin H, Surette MG. 2003. Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol. Microbiol. 50:1477-1491. http://dx.doi.org/10.1046/j.1365-2958.2003.03803.x.
346. Ryan RP, Dow JM. 2008. Diffusible signals and interspecies communication in bacteria. Microbiology 154:1845-1858. http://dx.doi.org/10.1099/mic.0.2008/017871-0.
347. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC. 2008. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 105: 15070-15075. http://dx.doi.org/10.1073/pnas.0804326105.
348. Fugere A, Lalonde Seguin D, Mitchell G, Deziel E, Dekimpe V, Cantin AM, Frost E, Malouin F. 2014. Interspecific small molecule interactions between clinical isolates of Pseudomonas aeruginosa and Staphylococcus aureus from adult cystic fibrosis patients. PLoS One 9:86705. http://dx.doi.org/10.1371/journal.pone.0086705.
349. Bjarnsholt T, Jensen PØ, Jakobsen TH, Phipps R, Nielsen AK, Rybtke MT, Tolker-Nielsen T, Givkov M, Hoiby N, Ciofu O. 2010. Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS One 5:10115. http://dx.doi.org/10.1371/journal.pone.0010115.
350. Pesci E, Milbank JBJ, Pearson JP, McKnight S, Kende AS, Greenberg EP, Iglewski BH. 1999. Quinolones signalling in the cell-to-cell communication system of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U.S.A. 96:11229-11234. http://dx.doi.org/10.1073/pnas.96.20.11229.
351. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Green-berg EP. 2000. Quorum sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407:762-764. http://dx.doi.org/10.1038/35037627.
352. Erickson DL, Endersby R, Kirkham A, Stuber K, Vollman DD, Rabin HR, Mitchell I, Storey DG. 2002. Pseudomonas aeruginosa quorum sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. Infect. Immun. 70:1783-1790. http://dx.doi.org/10.1128/IAI.70.4.1783-1790.2002.
353. Tateda K, Comte R, Pechere JC, Kohler T, Yamaguchi K, van Delden C. 2001. Azithromycin inhibits quorum sensing in Pseudomonas aerugi-nosa. Antimicrob. Agents Chemother. 45:1930-1933. http://dx.doi.org/10.1128/AAC.45.6.1930-1933.2001.
354. Skindersoe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB, Bjarnsholt T, Tolker-Nielsen T, Hoiby N, Givskov M. 2008. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimi-crob. Agents Chemother. 52:3648-3663. http://dx.doi.org/10.1128/AAC.01230-07.
355. Linares JF, Gustafsson I, Baquero F, Martinez JL. 2006. Antibiotics as intermicrobial signaling agents instead of weapons. Proc. Natl. Acad. Sci. U. S. A. 103:19484-19489. http://dx.doi.org/10.1073/pnas.0608949103.
356. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. 1996. The influence of azithromycin on the biofilm formation of Pseu-domonas aeruginosa in vitro. Chemotherapy 42:186-191. http://dx.doi.org/10.1159/000239440.
357. Kohler T, Perron GG, Buckling A, van Delden C. 2010. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog. 6:883. http://dx.doi.org/10.1371/journal.ppat.1000883.
358. Willner D, Haynes MR, Furlan M, Schmieder R, Lim YW, Rainey PB, Rohwer F, Conrad D. 2012. Spatial distribution of microbial communities in the cystic fibrosis lung. ISME J. 6:471-474. http://dx.doi.org/10.1038/ismej.2011.104.
359. Lynch SV, Bruce KD. 2013. The cystic fibrosis airway microbiome. Cold Spring Harb. Perspect. Med. 3:9738. http://dx.doi.org/10.1101/cshperspect.a009738.
360. Sibley CD, Rabin H, Surette MG. 2006. Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol. 1:53-61. http://dx.doi.org/10.2217/17460913.1.1.53.
361. Sibley CD, Duan K, Fischer C, Parkins MD, Storey DG, Rabin HR, Surette MG. 2008. Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog. 4:184. http://dx.doi.org/10.1371/journal.ppat.1000184.
362. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG. 2008. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 105:15070-15075. http://dx.doi.org/10.1073/pnas.0804326105.
363. Sibley CD, Parkins MD, Rabin HR, Surette MG. 2009. The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis. Curr. Opin. Invest. Drugs 10:787-794.
364. Rabin HR, Surette MG. 2012. The cystic fibrosis airway microbiome. Curr. Opin. Pulm. Med. 18:622-627. http://dx.doi.org/10.1097/MCP.0b013e328358d49a.
365. Rogers GB, Carroll MP, Serisier D., Hockey PM, Jones G, Bruce KD. 2004. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 42:5176-5183. http://dx.doi.org/10.1128/JCM.42.11.5176-5183.2004.
366. Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG, Sogin ML, O’Toole GA. 2013. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome 1:27. http://dx.doi.org/10.1186/2049-2618-1-27.
367. Sibley CD, Sibley KA, Leong TA, Grinwis ME, Parkins MD, Rabin HR, Surette MG. 2010. The Streptococcus milleri population of a cystic fibro-sis clinic reveals patient specificity and intraspecies diversity. J. Clin. Mi-crobiol. 48:2592-2594. http://dx.doi.org/10.1128/JCM.00414-10.
368. Rogers GB, Hoffman LR, Whiteley M, Daniels TWV, Carroll MP, Bruce KD. 2010. Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy. Trends Microbiol. 18:357-364. http://dx.doi.org/10.1016/j.tim.2010.04.005.
369. Contrepois A, Brion N, Garaud JJ, Faurisson F, Delatour F, Levy JC, Deybach JC, Carbon C. 1985. Renal disposition of gentamicin, dibeka-cin, tobramycin, netilmicin, and amikacin in humans. Antimicrob. Agents Chemother. 27:520-524. http://dx.doi.org/10.1128/AAC.27.4.520.
370. Canis F, Husson MO, Turck D, Vic P, Launay V, Ategbo S, Vincent A, Courcol RJ. 1997. Pharmacokinetics and bronchial diffusion of single daily dose amikacin incysticfibrosis patients. J.Antimicrob. Chemother. 39:431-433. http://dx.doi.org/10.1093/jac/39.3.431.
371. Autret E, Marchand S, Breteau M, Grenier B. 1986. Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion. Eur. J. Clin. Pharmacol. 31:79-83. http://dx.doi.org/10.1007/BF00870991.
372. Anonymous. 2012. A study of tobramycin inhalation powder from a modified manufacturing process versus placebo (EDIT). Clinical Trials no. NCT00918957, last update October 2012. https://ClinicalTrials.gov/.
373. Minic P, Fustik S, Solyom E, Mazurek H, Antipkin Y, Feketeova A, Senatorova A, Csiszer E, Kostromina V, Takac B, Ujhelyi R, Govan J, Slee A, Gupta R. 2011. A multi-cycle open-label study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection, abstr 217. Abstr. 34th Eur. Cyst. Fibros. Soc. Conf., Cologne, Germany.
374. Breidenstein EBM, Khaira BK, Wiegand I, Overhage J, Hancock REW. 2008. Complex ciprofloxacin resistome revealed by screening a Pseu-domonas aeruginosa mutant library for altered susceptibility. Antimi-crob. Agents Chemother. 52:4486-4491. http://dx.doi.org/10.1128/AAC.00222-08.